• Senti Biosciences Holdings posted a net loss of USD 4.22 million for the quarter ended March 31, 2026, narrowing from a net loss of USD 14.11 million a year earlier.
• Operating loss improved to USD 4.62 million from USD 16.4 million, helped by a USD 6.88 million gain on lease modification tied to the Alameda Lease Amendment.
• Research and development expense fell to USD 5.28 million from USD 9.28 million, while general and administrative expense declined to USD 6.23 million from USD 7.12 million.
• Cash and cash equivalents totaled USD 8.9 million at March 31, 2026, down from USD 16.4 million at year-end 2025, with USD 7.48 million used in operating activities during the quarter.
• Subsequent to quarter-end, Senti completed a holding company reorganization on April 24, 2026, then signed a securities purchase agreement on April 27, 2026 for up to USD 40 million of senior secured convertible notes, including an initial USD 10 million tranche.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Senti Biosciences Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-035126), on May 14, 2026, and is solely responsible for the information contained therein.